AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01672476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80mg
Study NCT03927456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT00434642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
Study NCT00434642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
Study NCT04120363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: single intramuscular injection of 750 mg testosterone undecanoate
Study NCT04120363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sesame Oil
Description: single intramuscular injection of 750 mg sesame oil solution
Study NCT02191332 — intervention group
Intervention type: DRUG
Intervention: Viramune
Study NCT04447586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer
Description: Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study.
Study NCT01251861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01251861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given PO
Study NCT01251861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT01251861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo clinical observation
Study NCT01251861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01251861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04499859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg + Rosuvastatin 5mg
Description: Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
Study NCT04499859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: 20mg of Rosuvastatin as a standard treatment for AMI patients
Study NCT02055378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: topical 0.125% atropine eye drops
Study NCT03927456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
Study NCT02055378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: topical 0.125% atropine eye drops
Study NCT02055378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricular acupoint stimulation
Description: Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
Study NCT03927456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
Study NCT02350816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGT-1410
Description: HGT-1410 administered according to Patient Group assignment.
Study NCT04251247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: D-dimer/fibrinogen ratio
Description: The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
Study NCT01289054 — intervention group
Intervention type: DRUG
Intervention: Tasigna
Study NCT01289054 — intervention group
Intervention type: DRUG
Intervention: Gleevec
Study NCT00842192 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
Study NCT01531660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: step-up jogging program
Study NCT03261505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
Study NCT03261505 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
Study NCT03261505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
Study NCT03261505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
Study NCT00820781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portacaval shunt
Description: Subject taken to the operating room and undergoes portacaval shunt surgery
Study NCT00820781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
Study NCT02875990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT00667680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator
Description: real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
Study NCT00667680 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator
Description: real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
Study NCT00923897 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative RT
Description: Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
Study NCT03623191 — intervention group
Intervention type: OTHER
Intervention: Clinical examination
Study NCT04018651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Master Adherence Intervention
Description: The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~1. Importance of daily adherence;~2. Three week delay for full effectiveness describing PrEP like taking the birth control pill;~3. Condom use for other sexually transmitted infection (STI) prevention;~4. Pregnancy prevention plans;~5. Plans for follow up calls~6. Referral to other treatment services if necessary
Study NCT02704169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spatially registered endoscopy
Study NCT01657435 — intervention group
Intervention type: DEVICE
Intervention: Ceramax Acetabular System
Description: 28mm Ceramic-on-ceramic Acetabular Cup System
Study NCT03763006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eyelid cleaning
Description: This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
Study NCT03763006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid cleaning
Description: This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
Study NCT01370031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenil® Modulite® via AeroChamber Plus™
Description: Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
Study NCT01365858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy).
Study NCT01365858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy).
Study NCT03118089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuit style oral nutritional supplement
Study NCT01672476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Fimasartan 30mg
Study NCT02165046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Study NCT02165046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Study NCT02165046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaterol
Study NCT02165046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol
Study NCT01828372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: additional blood withdrawals
Description: Blood withdrawals by either venous puncture or placement of permanent venous catheter.
Study NCT00454168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1 leukemia peptide vaccine
Description: Given subcutaneously
Study NCT00454168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study NCT00454168 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Description: Given subcutaneously
Study NCT00454168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given subcutaneously
Study NCT03367377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC
Study NCT03367377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT04049656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFVI
Description: Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
Study NCT03476304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocrown restoration
Description: The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
Study NCT03476304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post retained composite restoration
Description: The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
Study NCT03476304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post retained ceramic restoration
Description: The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
Study NCT01306370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule
Study NCT01306370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: Topical administration, before to close the surgical wound. Dosage: 2 mL.
Study NCT01306370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: Topical administration, before to close the surgical wound.
Study NCT01306370 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Habitual haemostasis
Description: The surgical habitual haemostasis.
Study NCT02469116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02469116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02469116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Study NCT03496688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus floor augmentation
Study NCT04447586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure measurement during exhalation through an alternative PEP device/soft drink straw.
Description: Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets.
Study NCT01251588 — intervention group
Intervention type: BIOLOGICAL
Intervention: autologous cultured chondrocytes on porcine collagen membrane
Description: Implantation received in the previous MACI00206 study
Study NCT01251588 — intervention group
Intervention type: PROCEDURE
Intervention: Microfracture
Description: Arthroscopic Microfracture treatment received in the previous MACI00206 study
Study NCT04563091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis with online HFR
Description: 1. Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values > 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~2. Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~3. Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~4. Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment.
Study NCT03034785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexiMitt
Description: The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
Study NCT04413084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze stability exercises
Description: Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.
Study NCT04413084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brandt-Daroff Exercises
Description: Brandt-Daroff Exercises~1. Start sitting upright on the edge of the bed.~2. Turn your head 45 degrees to the left, or as far as is comfortable.~3. Lie down on your right side.~4. Remain in this position for 30 seconds or until any dizziness has subsided.~5. Sit up and turn head back to center.~6. Turn your head 45 degrees to the right, or as far as is comfortable.~7. Lie down on your left side.~8. Remain in this position for 30 seconds or until any dizziness has subsided.~9. Sit up and turn head back to center.
Study NCT01998451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Description: patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
Study NCT01998451 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tauroursodeoxycholic acid
Description: patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
Study NCT01750580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Study NCT01750580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT04614688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education Platform
Description: The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
Study NCT03239626 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: POHIM-RT
Description: postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
Study NCT01370031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clenil® Modulite® via Volumatic™ spacer
Description: Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
Study NCT01370031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenil® Modulite® via AeroChamber Plus™ plus charcoal block
Description: Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
Study NCT01370031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
Description: Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
Study NCT01025089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Description: Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
Study NCT02514889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-counting
Description: The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls.
Study NCT02514889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlate
Description: The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls.
Study NCT00740116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery